JPM 2026: FDA panelists prioritize faster approvals, national security, AI, and more

Start
Speaking at the 2026 J.P. Morgan Healthcare Conference, Hogan Lovells global regulatory partners Elizabeth Jungman and Brian Carey moderated a panel discussion with U.S. Food and Drug Administration (FDA) Deputy Chief of Staff Samuel Doran and FDA Office of the Commissioner Senior Advisor Karim Mikhail….
By: Hogan Lovells
Previous Story

Client Alert: Snow, Ice and Exposure – Managing Winter Risk in Community Associations

Next Story

Innovation Within Limits, January 2026 – Insured State Member Banks Receive Support to Engage in Crypto-Asset Activities